A quarter of children with non-Hodgkin's lymphoma (NHL) present with anterior mediastinal masses, the majority of which have lymphoblastic histology with a T cell origin.
/l with a differential of 30% segmented neutrophils, 3% bands, 49% lymphocytes, 3% monocytes, 2% eosinophils, 6% myelocytes, 4% metamyelocytes, and 3% blasts. Blood chemistries were normal except for a uric acid of 8.8 mg/dl and lactate dehydrogenase of 14 747 U/l. Following the diagnostic workup described below, the patients was treated according to the LMB89 regimen. 4 She had a slow response to therapy, relapsed 4 months from diagnosis, and died of progressive disease 2 months later.
Posteroanterior chest radiograph at presentation showed a large mediastinal mass with shift of the mediastinum to the right of the midline and a left pleural effusion ( Figure 1a ). Computed tomographic (CT) imaging of the chest demonstrated a large inhomogeneously enhancing anterior mediastinal mass with displacement of the great vessels and left subclavian vein posteriorly, as well as compression of the left lung (Figure 1b) . CT imaging of the abdomen was normal.
Bone marrow aspirate at presentation revealed hypercellular spicules with infiltrate of moderately large blasts with abundant deep blue vacuolated cytoplasm, moderately large regular nuclei, and several indistinct nucleoli (Figure 2 ), features of L3-ALL. The blasts were negative for myeloperoxidase, Sudan black and ␣-naphthyl butyrate esterase. By flow cytometric analysis, the leukemic blasts were positive for Bone marrow aspirate at presentation. Marrow was effaced by an infiltrate of large blasts with abundant deep blue vacuolated cytoplasm, moderately large regular nuclei, and several indistinct nucleoli.
HLA-DR, CD45, CD10, CD19, CD20, CD21, CD22, and surface immunoglobulin heavy chain alpha. The blasts did not express TdT or CD34. All T cell and myeloid markers were negative. In addition, there was no detectable cytoplasmic or surface immunoglobulin mu, kappa, lambda, delta, or gamma.
Chromosome analysis revealed one abnormal stem line with the following karyotype: 46,XX,t(3;22)(q27;q11), t(8;14)(q24;q32).
Southern blot analysis was performed on genomic DNA isolated from the patient's leukemic blasts to investigate the status of the BCL6, immunoglobulin heavy chain, and c-MYC genes. Briefly, 10 g of DNA was digested with various restriction enzymes, separated electrophoretically in 0.8% agarose gels, and transferred to nylon membranes. Hybridization of XbaI-digested DNA with a BCL6-specific probe (Sac 4.0 probe, kindly provided by Dr R Dalla-Favera, Columbia University, New York) revealed an abnormal 6.6 kb restriction fragment (Figure 3 ), representing rearrangement of BCL6. Digests with BamHI/HindIII, BglII, and XbaI demonstrated two rearranged mu chain genes (data not shown) when probed with IghHJ6 (Dako, Carpinteria, CA, USA). A rearranged c-MYC gene was detected in blots of DNA digested with EcoRI, XbaI and HindIII (data not shown) using a cDNA probe to exon 1 of c-MYC (HP132; Oncogene Research, Cambridge, MA, USA).
Discussion
Children with NHL often present with extranodal disease, with 26% of cases involving the mediastinum. 1 Although most of these cases are associated with lymphoblastic histology, 5% of NHL cases may present as primary mediastinal nonlymphoblastic lymphoma. 2 However, Burkitt lymphoma of the mediastinum is rare. A review of 25 cases of mediastinal nonlymphoblastic lymphoma revealed large cell immunoblastic histology in 20 cases, intermediate grade tumors in four cases, and small noncleaved non-Burkitt histology without bone marrow involvement in one case. 2 Another pathologic review of 48 cases of mediastinal NHL treated on Children's Cancer Group protocols demonstrated lymphoblastic histology in 40 cases, large cell lymphoma in five cases, and non-Burkitt pleomorphic histology in three cases. 3 Again, no cases of media- stinal lymphoma with typical Burkitt morphology were reported. Clinical studies of B cell lymphoma and ALL also demonstrate a lack of mediastinal Burkitt lymphoma. In one study of 216 B cell patients, only two had disease in the chest. 5 Similarly, no cases of mediastinal disease were reported among 87 cases of B cell ALL treated on BFM trials. 6 The case described here demonstrates the unusual occurrence of B cell ALL presenting as a mediastinal mass and emphasizes the need for a complete diagnostic evaluation of all mediastinal masses. Although this patient was initially thought to have lymphoblastic lymphoma with bone marrow involvement, her bone marrow aspirate showed the presence of FAB-L3 lymphoblasts. Further studies demonstrated surface immunoglobulin heavy chains, c-MYC rearrangement, and t(8;14)(q24;q32), confirming the diagnosis of B cell leukemia.
The presence of surface alpha immunoglobulin heavy chains without detectable kappa or lambda light is an unexpected finding in Burkitt lymphoma. One potential explanation is that the phenotype in this case was actually transitional pre-B and expressed surrogate light chains. 7, 8 However, expression of surrogate light chains has not been reported in association with alpha heavy chains. In addition, the polyclonal lambda antibody used here will detect surrogate lambda light chain. Other possible explanations for the absence of light chains include the absence of kappa or lambda protein because of defective transcription or translation of light chain mRNA, use of insensitive assays for light chain expression, or inability of the antibodies used to recognize truncated or defective light chain proteins. Under normal conditions, binding of alpha heavy chains to the surface of B cells requires the presence of kappa or lambda light chains. Thus, it seems unlikely that kappa or lambda light chain genes were not rearranged and transcribed. Lack of detectable immunoglobulin due to an insensitive assay is also unlikely, because polyclonal immunoglobulin antisera of high quality from two different sources were used in flow cytometric analysis. Hence, conceivably this case had a truncated or defective kappa or lambda light chain that was not recognized by the polyclonal antibodies.
Of greater interest, the leukemic clone in this case contained, in addition to the t(8;14), the t(3;22)(q27;q11), a translocation that has previously been reported in diffuse large cell lymphomas and follicular lymphomas, but not in Burkitt lymphoma. 6, 9, 10 In diffuse large cell lymphoma, the t(3;22) disrupts the BCL6 proto-oncogene in its 5Ј noncoding region, leading to deregulated protein expression. [11] [12] [13] [14] Rearrangements of BCL6 have been reported most often in diffuse large cell lymphoma, but are also seen, albeit at a lower frequency, in follicular lymphoma. BCL6 rearrangements have not been reported in other types of NHL or in ALL. Southern blot analysis of the case presented here revealed clear evidence of BCL6 rearrangement, which occurred as a consequence of translocation to site of the light chain gene (3q27). This novel case, therefore, demonstrates BCL6 involvement in B cell ALL, as well as rearrangement of BCL6 and c-MYC in the same clone. Although the simultaneous occurrence of the t(3;22) and t(8;14) has not been previously reported, two translocations involving the immunoglobulin genes may occur concurrently. For example, the t(3;22) may occur in cases of follicular lymphoma that also carry the t(14;18) 10 and cell lines that harbor alterations of c-MYC and BCL6 have been established. 15 In summary, we stress the need for a thorough morphologic, immunophenotypic, and cytogenetic assessment of all pediatric malignancies. When possible, molecular genetic studies should also be performed. These studies may improve both diagnostic accuracy and treatment selection. 16 
